Obsidian Therapeutics Inc.
OBXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 28, 2026 | $-1.38 | $-1.63 | — | — |
| Aug 14, 2024 | $-14.00 | $165.45 | — | $50.0M |
| May 13, 2024 | $-16.00 | $-58.89 | — | — |
| Nov 14, 2023 | $-66.00 | $-79.44 | — | — |
| Aug 14, 2023 | $-96.00 | $-75.66 | — | — |
News
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced positive updated results in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsokigene autoleucel (amsoki-ce.
Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsoki.
Obsidian Therapeutics (NASDAQ: OBX - Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 253,084 shares, a growth of 210.7% from the August 31st total of 81,457 shares. Approximately 0.4% of the company's shares are sold short. Based
Obsidian Therapeutics is rated Hold due to overvaluation despite promising cell therapy technology targeting solid tumors. OBX-115, the lead asset, shows strong early efficacy and safety in advanced melanoma, but is only in Phase 1/2 trials. Current $1.1B market cap implies high expectations; risk-adjusted fair value is $10.16/share versus ~$17.00 trading price.